FTD pipeline
Track FTD programs anchored in progranulin, GRN replacement, C9 biology, and other genetics-led strategies.
Top programs in this hub
Starts with the highest-priority programs in the current dataset, then widens into the full bench below.
Gene-therapy FTD program that helps make the monitor feel like a real neurodegeneration pipeline rather than an Alzheimer's side project.
- Mechanism
- GRN gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Early safety and biological activity signals in GRN-FTD.
- Last verified
- 20 Apr 2026
FTD program targeting the progranulin pathway through sortilin inhibition.
- Mechanism
- sortilin inhibition / progranulin elevation
- Modality
- monoclonal antibody
- Next catalyst
- Mid-stage readouts and biomarker alignment.
- Last verified
- 20 Apr 2026
A major FTD progranulin program that now functions as an important field-level setback reference rather than an active growth story.
- Mechanism
- progranulin elevation
- Modality
- monoclonal antibody
- Next catalyst
- No near-term active catalyst, but it matters as context for the FTD field.
- Last verified
- 20 Apr 2026
What defines this bench
Quick pattern read on the mechanisms and modalities currently showing up most often.
A disease-specific view of the main programs, the common mechanisms, and the related program pages.
All tracked Frontotemporal dementia programs
Every program in the current watchlist for this disease, in priority order.
Gene-therapy FTD program that helps make the monitor feel like a real neurodegeneration pipeline rather than an Alzheimer's side project.
- Mechanism
- GRN gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Early safety and biological activity signals in GRN-FTD.
- Last verified
- 20 Apr 2026
FTD program targeting the progranulin pathway through sortilin inhibition.
- Mechanism
- sortilin inhibition / progranulin elevation
- Modality
- monoclonal antibody
- Next catalyst
- Mid-stage readouts and biomarker alignment.
- Last verified
- 20 Apr 2026
A major FTD progranulin program that now functions as an important field-level setback reference rather than an active growth story.
- Mechanism
- progranulin elevation
- Modality
- monoclonal antibody
- Next catalyst
- No near-term active catalyst, but it matters as context for the FTD field.
- Last verified
- 20 Apr 2026
A genetically anchored ALS/FTD program whose termination is still important context for anyone taking the pipeline seriously.
- Mechanism
- C9orf72-targeted oligonucleotide
- Modality
- oligonucleotide
- Next catalyst
- No active catalyst, but it remains a useful reference point for C9-directed clinical translation.
- Last verified
- 20 Apr 2026
Related pages
Research, key targets, Discover, and ways to contribute.
Other disease hubs
Other disease areas in the pipeline.
Track the mix of amyloid, tau, metabolic, and precision-style Alzheimer's programs worth watching.
Disease hub Parkinson's pipelineFollow Parkinson's programs spanning alpha-synuclein, GBA biology, gene therapy, and mechanistic repurposing.
Disease hub ALS pipelineTrack ALS programs across genetic targeting, stress-response biology, cell therapy, and platform-trial bets.
Disease hub Huntington's pipelineTrack Huntington's programs across gene therapy, antisense, allele-selective, and small-molecule huntingtin-lowering approaches.